LINGO2
Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 2
Also known as: LERN3, LIGO2_HUMAN, LRRN6C
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q7L985
- Gene
- LINGO2
- Ensembl
- ENSG00000174482
- Chromosome
- 9
- Canonical length
- 606 aa
- Protein class
- Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Nucleoplasm,Cytoplasmic bodies
OverviewNCBI Gene
Predicted to act upstream of or within positive regulation of synapse assembly. Predicted to be located in membrane. Predicted to be active in several cellular components, including extracellular space; glutamatergic synapse; and synaptic membrane. [provided by Alliance of Genome Resources, Apr 2025]
Canonical amino-acid sequenceUniProt
606 residues, UniProt reviewed canonical sequence.
>Q7L985|LINGO2
1 MLHTAISCWQ PFLGLAVVLI FMGSTIGCPA RCECSAQNKS VSCHRRRLIA IPEGIPIETK
61 ILDLSKNRLK SVNPEEFISY PLLEEIDLSD NIIANVEPGA FNNLFNLRSL RLKGNRLKLV
121 PLGVFTGLSN LTKLDISENK IVILLDYMFQ DLHNLKSLEV GDNDLVYISH RAFSGLLSLE
181 QLTLEKCNLT AVPTEALSHL RSLISLHLKH LNINNMPVYA FKRLFHLKHL EIDYWPLLDM
241 MPANSLYGLN LTSLSVTNTN LSTVPFLAFK HLVYLTHLNL SYNPISTIEA GMFSDLIRLQ
301 ELHIVGAQLR TIEPHSFQGL RFLRVLNVSQ NLLETLEENV FSSPRALEVL SINNNPLACD
361 CRLLWILQRQ PTLQFGGQQP MCAGPDTIRE RSFKDFHSTA LSFYFTCKKP KIREKKLQHL
421 LVDEGQTVQL ECSADGDPQP VISWVTPRRR FITTKSNGRA TVLGDGTLEI RFAQDQDSGM
481 YVCIASNAAG NDTFTASLTV KGFASDRFLY ANRTPMYMTD SNDTISNGTN ANTFSLDLKT
541 ILVSTAMGCF TFLGVVLFCF LLLFVWSRGK GKHKNSIDLE YVPRKNNGAV VEGEVAGPRR
601 FNMKMILocalizationUniProt · AlphaFold · HPA
Whether an antibody against LINGO2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.34
- Highest tissue expression
- 8.2 nTPM
Expression across tissuesHPA
Tissue
- smooth muscle: 8.2 nTPM
- endometrium: 7.3 nTPM
- thyroid gland: 2.9 nTPM
- cerebral cortex: 2.5 nTPM
- hypothalamus: 2.5 nTPM
- retina: 2.5 nTPM
Single-cell type
- retinal bipolar cells: 887 nCPM
- brain inhibitory neurons: 863 nCPM
- adrenal medulla cells: 851 nCPM
- brain excitatory neurons: 809 nCPM
- retinal ganglion cells: 804 nCPM
- other brain neurons: 722 nCPM
Immune cell
- NK-cell: 1.3 nTPM
- total PBMC: 0.6 nTPM
- gdT-cell: 0.1 nTPM
- memory CD8 T-cell: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
Brain region
- hypothalamus: 28 nTPM
- cerebral cortex: 27 nTPM
- basal ganglia: 18 nTPM
- thalamus: 15 nTPM
- amygdala: 15 nTPM
- white matter: 15 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.42
- gnomAD pLI
- 0.86
- gnomAD missense Z
- 0.67
- DepMap mean gene effect
- 0.06
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Leucine-rich repeat N-terminal domain
- Leucine-rich repeat
- Leucine-rich repeat, typical subtype
- Immunoglobulin subtype 2
- Immunoglobulin domain subtype
- Immunoglobulin-like domain
- Immunoglobulin I-set
- Immunoglobulin-like fold
- Leucine-rich repeat domain superfamily
- Immunoglobulin-like domain superfamily
- Leucine-rich repeat and transmembrane domain-containing protein
- Leucine Rich Repeat
- Immunoglobulin I-set domain
- Leucine rich repeat
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LINGO2 as an antibody target. Whether an autoantibody or antibody against LINGO2 could matter depends on whether native LINGO2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LINGO2 is annotated at the cell surface, where native LINGO2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label LINGO2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...